Genomics-based testing producer Genetic Technologies Ltd (ASX:GTG) believes its geneType Risk Assessment tests – sold in Australia and the United States – have the potential to clearly identify people with serious risk of disease or cancer, finding that of those tested in both countries, 79.5 percent of people have been found to have an elevated risk for at least one disease.
The test – which is non-invasive, using a saliva sample – helps customers identify their risk of common but serious diseases, including breast, ovarian, pancreatic, prostate, colorectal, and melanoma cancers, cardiovascular diseases and metabolic conditions such as Type 2 diabetes.
Since the conditions tested for account for 70 percent of annual mortality and morbidities – and provide customers with information about their genetic predisposition to these – Genetic Technologies argues that the ‘Multi-Risk’ test can provide customers with a better understanding of their individual health risks, according to geneType CEO Simon Morriss.
“We have always believed the geneType Multi-Risk Test is a major step forward in personalised medicine,” he said.
“These real time results validate the utility of geneType in identifying people at high risk of disease, and importantly, they enable individuals and healthcare providers to take control of their health.”
Genetic Technologies has been trading at 8 cents.
